Oligonucleotide therapeutics in cancer

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• Aberrant pre-mRNA splicing is linked to gene expression changes and cellular transformation, driving cancer development.
• Oligonucleotide therapeutics represent a class of drugs designed to modulate gene expression for disease treatment.
• Antisense oligonucleotides and splice switching oligonucleotides (SSO) are key examples of oligonucleotide therapeutics.

Purpose of the Study:

• To review the progress and application of oligonucleotide therapeutics in cancer treatment.
• To highlight the mechanisms of action for antisense oligonucleotides and SSO in targeting cancer-related gene expression.
• To discuss the potential of these nucleic acid-based drugs in improving cancer therapy.

Main Methods:

• RNase H-dependent mechanism utilized by antisense oligonucleotides to downregulate target mRNA.
• RNase H-independent modulation of alternative splicing by splice switching oligonucleotides (SSO).
• Review of current research and clinical applications of oligonucleotide-based cancer therapies.

Main Results:

• Antisense oligonucleotides effectively reduce the expression of specific genes implicated in cancer.
• SSOs can correct aberrant splicing patterns, leading to the production of functional proteins or reduced oncogenic activity.
• Significant advancements have been made in developing and applying these oligonucleotide drugs for various cancers.

Conclusions:

• Oligonucleotide therapeutics demonstrate significant promise as a novel approach to cancer treatment.
• Targeting pre-mRNA splicing offers a powerful strategy for controlling cancer gene expression.
• Continued research and development in oligonucleotide drug delivery and specificity will further enhance their therapeutic potential in oncology.